The warning as each document words it
All three documents describe the same chain, from digestive side effects to fluid loss to kidney strain, but they put the emphasis in different places [1][2][3].
| Document | What it says | Monitoring advice |
|---|---|---|
| US PI 5.5 and 6.2 [1] | Acute kidney injury reported after approval, some needing haemodialysis; most cases followed dehydration from nausea, vomiting or diarrhoea | Check kidney function when such reactions occur, especially at the start and after dose increases |
| Canadian PM 4.2 and 7 [3] | Acute kidney failure and worsening chronic kidney failure after approval; some in people without known kidney disease | Monitor kidney function in severe nausea, vomiting or diarrhoea |
| EU SmPC 4.4 [2] | Dehydration from digestive effects can, in rare cases, worsen kidney function | Advise patients about dehydration and avoiding fluid loss |
Where the fluid loss comes from, and when
In the two placebo-controlled trials behind the US table (Trial 1 and Trial 6), nausea was reported by 20% on 14 mg, diarrhoea by 10% and vomiting by 8%, against 6%, 4% and 3% on placebo [1]. Most of these reports came while the dose was being stepped up: 3 mg for days 1 to 30, 7 mg for days 31 to 60 and, for some, 14 mg from day 61 [1]. That is why the US label singles out the start and each increase.
MedlinePlus lists vomiting and diarrhoea among the main ways the body loses too much fluid, and notes that people with diabetes are at higher risk of dehydration [8]. Early signs include thirst, a dry mouth, passing little urine and dark yellow urine [8].
What long trials show for kidney outcomes
SOUL, the US label’s Trial 7, followed 9,650 people with type 2 diabetes and heart disease, kidney disease or both for a median of about four years; 40% had chronic kidney disease [1]. Its first confirmatory kidney endpoint, a composite of kidney failure, a large drop in kidney function, kidney death or cardiovascular death, gave a hazard ratio of 0.91, with a confidence interval from 0.80 to 1.05 [2]. The trial report states that the confirmatory secondary outcomes did not differ significantly from placebo [4].
A 2026 prespecified pooled analysis combined SOUL with two trials of injected semaglutide, FLOW and SELECT, in 30,787 participants. Major kidney events were less frequent on semaglutide (hazard ratio 0.84) [5]. The trials used different doses and routes and the analysis was funded by the manufacturer, so it cannot isolate the tablet [5]. None of this cancels the dehydration warning, which is about sudden, short-term injury.
What adverse-event reports show
In 2,398 US FDA reports for semaglutide tablets, kidney and urinary disorders made up 124 reports and did not stand out against other drugs; the reporting odds ratio was 1.13, with a confidence interval crossing 1 [6]. At the level of individual terms, only kidney pain appeared among the signals [6]. Reports cannot rule out rare harm, and the US label still lists acute kidney injury among post-approval reports [1][6].
If you already have kidney disease
The recommended dose is the same with mild, moderate or severe kidney impairment [1][2]. Trial 5 studied 14 mg against placebo in 324 adults with moderate impairment, average age 70, and the label reports no clinically relevant change in semaglutide levels across kidney impairment, including end-stage disease [1]. Canada saw no overall safety differences in that trial [3]. Europe and Canada note that experience in end-stage kidney disease is limited [2][3].
Canada and the EU leaflet stress that drinking enough fluid is especially important if you have kidney problems [2][3]. The Medication Guide asks you to mention any past or current kidney problems before you start [1]. If your fluids are restricted for another condition, ask your care team how this advice applies to you.
Other causes of sudden kidney injury
MedlinePlus lists very low blood pressure from dehydration, bleeding, burns or serious illness; kidney infections and sepsis; urinary blockage; and several medicines, including non-steroidal anti-inflammatory painkillers (NSAIDs), certain antibiotics and blood pressure medicines, and contrast dye used in scans [7]. Blood pressure medicines are common alongside Rybelsus®: in SOUL, 79% of participants took an ACE inhibitor or an angiotensin receptor blocker [1]. A list of everything you use helps your prescriber judge your risk on days when you are unwell.
For dehydration itself, MedlinePlus suggests sipping water, sucking ice chips or drinking an electrolyte sports drink, and warns against salt tablets [8]. The Rybelsus® labels set no daily fluid amount [1][2][3].
Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Confusion, fainting or loss of consciousness during vomiting or diarrhoea | Emergency services (911) | Emergency | MedlinePlus [8] |
| Very little or no urine, or urine that stops | Your provider right away | Today | MedlinePlus [7] |
| Nausea, vomiting or diarrhoea that does not go away | Your prescriber, right away | Today | Rybelsus® Medication Guide [1] |
| New swelling of the legs, ankles or feet, shortness of breath or unusual tiredness | Your provider | Today | MedlinePlus [7] |
| Known kidney disease, dialysis or a planned scan with contrast dye | Your prescriber and the team doing the scan | At your next appointment | Rybelsus® Medication Guide [1]; MedlinePlus [7] |
